Emma is a Registered Nurse; she qualified in 1990 having undertaken a BSc in Nursing with Economics at St Bartholomew's Hospital in conjunction with City University. She worked in general and oncology nursing before moving into academia at King's College London. She was awarded her MSc in Nursing from King's College London (1995) and later her doctorate (2002) for her work developing and evaluating an intervention for cancer-related fatigue.
Emma held various research and teaching posts at King's College London before being conferred the title Professor of Supportive Cancer Care in 2009 in recognition of her contribution to cancer and palliative care nursing and her outstanding research profile and academic leadership. In 2011 she was awarded a King's College London Supervisory Excellence Award for excellence in postgraduate research supervision.
At King's College London she led the Supportive Cancer Care Research Group and provided strategic leadership in the Florence Nightingale Faculty of Nursing and Midwifery for cancer and palliative nursing education and research. She has a research career spanning 25 years and is internationally recognised for her research in cancer care.
Emma's research programme aims to enhance supportive care provided to patients and their carers (family members/friends who share the experience of cancer with patients). It aims to help patients maximise the benefits of treatment whilst enabling patients and their carers to live as well as possible with the effects of the disease and consequences of its treatment. Key themes within her research programme include: determining unmet supportive care needs in people living with and beyond cancer; understanding impact of inequalities on experience and outcomes of cancer care; developing and evaluating complex interventions to facilitate supported self-management of symptoms (in particular fatigue) and enhance people's lives following treatment for cancer; and developing and evaluating interventions to enhance the role and wellbeing of carers. She has considerable experience of developing complex interventions and evaluating their outcomes through mixed method research designs.
1. EU 7th Framework Programme (2013; 60 months) Randomised controlled trial to evaluate electronic Symptom Management using the Advanced Symptom Management System (ASyMS) Remote Technology for patients with cancers (Kearney, Maguire, Ream et al) €5,999,991
2. National Institute of Health Research (2014; 36 months) Evaluating the feasibility and acceptability of early decongestive treatment for newly presenting breast cancer-related lymphedema (BCRL) of the upper limnb. Clinical doctoral research fellowship (Jeffs & Ream) £325, 969
3. Dimbleby Cancer Care (2014; 15 months) Walking for health in people with advanced cancer: a study to assess acceptability and feasibility (Armes, Purushotham, Ream, Van Helmrick) £74, 946
4. Big Lottery Fund (2010; 60 months) Improving breast cancer patients' wellbeing during transition to survivorship (Scanlon, Harding, Ream) £395,974
Emma provides strategic leadership for education in research across modules and programmes within the School.
Trailblazing study that uses artificial intelligence to support people with dementia scoops prestigious healthcare award
The aim of this study is to co-create an evidence-based and theoretically informed web-based intervention (RESTORE) designed to enhance self-efficacy to live with cancer-related fatigue (CRF) following primary cancer treatment.
A nine-step process informed the development of the intervention: (1) review of empirical literature; (2) review of existing patient resources; (3) establish theoretical framework; (4) establish design team with expertise in web-based interventions, CRF and people affected by cancer; (5) develop prototype intervention; (6) user testing phase 1; (7) refinement of prototype; (8) user testing phase 2; and (9) develop final intervention.
Key stakeholders made a critical contribution at every step of intervention development, and user testing, which involved an iterative process and resulted in the final intervention. The RESTORE intervention has five sessions; sessions 1 and 2 include an introduction to CRF and goal setting. Sessions 3?5 can be tailored to user preference and are designed to cover areas of life where CRF may have an impact: home and work life, personal relationships and emotional adjustment.
It is feasible to systematically ?co-create? an evidence-based and theory-driven web-based self-management intervention to support cancer survivors living with the consequences of cancer and its treatment. This is the first account of the development of a web-based intervention to support self-efficacy to manage CRF. An exploratory trial to test the feasibility and acceptability of RESTORE is now warranted. Copyright © 2015 John Wiley & Sons, Ltd.
Net survival rates for cancer are increasing worldwide, placing a strain on health service provision. There is a drive to transfer care of cancer survivors - individuals living with and beyond cancer - to the community and encourage them to play an active role in their own care. Telehealth, the use of technology in remote exchange of data and communication between patients and healthcare professionals, is an important contributor to this evolving model of care and may offer additional benefits to cancer survivors. Telehealth is a complex intervention and understanding patient experiences of it is important in evaluating its impact. However, a wider view of patient experience is lacking as qualitative studies detailing cancer survivor engagement with telehealth have yet to be synthesised.
Systematically identify, appraise and synthesise qualitative research evidence on the experiences of adult cancer survivors participating in telehealth intervention(s), to characterise the patient experience of telehealth interventions for this group.
Medline (PubMed), PsychINFO, CINAHL (Cumulative Index for Nursing and Allied Health Professionals), Embase and Cochrane Central Register of Controlled Trial were searched on 14th August 2015 and 8th March 2016 for English-language papers published between 2006 and 2016. Inclusion criteria were: adult cancer survivors aged 18 and over; cancer diagnosis; experience of participating in a telehealth intervention (defined as remote communication and/or remote monitoring with a healthcare professional(s) delivered by telephone, internet, or hand-held/mobile technology); reporting qualitative data including verbatim quotes. An adapted Critical Appraisal Skill Programme (CASP) Checklist for Qualitative Research was used to assess paper quality. The results section of each included article was coded line by line and all papers underwent inductive analysis, involving comparison, re-examination and grouping of codes to develop descriptive themes. Analytical themes were developed through an iterative process of reflection on, and interpretation of, the descriptive themes within and across studies.
22 papers were included. Three analytical themes emerged, each with three descriptive subthemes: 1. Influence of telehealth on the disrupted lives of cancer survivors a. Convenience b. Independence c. Burden 2. Personalised care in a virtual world a. Time b. Space c. The human factor 3. Remote reassurance ? a safety net of healthcare professional connection a. Active connection b. Passive connection c. Slipping through the net Telehealth interventions represent a convenient approach which can potentially minimise treatment burden and disruption to cancer survivors? lives. Telehealth interventions can facilitate an experience of personalised care and reassurance for those living with and beyond cancer, but it is important to consider individual factors when tailoring interventions to ensure engagement promotes benefit rather than burden.
Telehealth interventions can provide cancer survivors with both independence and reassurance; both important for everyday life or wellbeing. Future telehealth interventions need to be developed iteratively and in collaboration with a broad range of cancer survivors to maximise engagement and benefit.
Cancer-related fatigue is a significant clinical problem and is a symptom commonly experienced by patients with differing cancer types during and following treatment. It is a distressing symptom which interferes with functioning in daily life. However, much less is known about the prevalence and severity of fatigue in prostate cancer when compared to other cancer types, such as breast cancer.
A systematic review was conducted to appraise the prevalence and severity of cancer-related fatigue in prostate cancer. Systematic searches of published quantitative research relating to the prevalence and severity of fatigue were conducted using databases, including Medline, PsychINFO, CINAHL and ISI Web of Knowledge (January 2012). Included papers measured the prevalence or severity of prostate-cancer-related fatigue and differentiated fatigue outcomes (prevalence, severity) between treatment modalities.
Nineteen studies were eligible for the review, of which 17 were cross-sectional and 2 longitudinal. Findings suggest that the prevalence of any fatigue is as high as 74 %, whilst chronic fatigue prevalence was highest (39 %) when hormone therapy was combined with radiotherapy. Fatigue severity is reported as worse in hormone therapy and treatment combining hormone therapy and radiotherapy.
Fatigue is a common symptom for men with prostate cancer, particularly those prescribed hormone therapy. A wide variety of tools were used to measure fatigue prevalence and severity, which made comparisons across studies difficult. The review is limited by methodological shortcomings in the studies included.
and diagnosis with breast cancer among black women.
Design: Systematic review.
Methods: We searched multiple bibliographic
databases (January 1991?February 2013) for primary
research, published in English, conducted in
developed countries and investigating barriers to
early presentation and diagnosis with symptomatic
breast cancer among black women (e18 years).
Studies were excluded if they did not report separate
findings by ethnic group or gender, only reported
differences in time to presentation/diagnosis, or
reported on interventions and barriers to cancer
screening. We followed Cochrane and PRISMA
guidance to identify relevant research. Findings were
integrated through thematic synthesis. Designs of
quantitative studies made meta-analysis impossible.
Results: We identified 18 studies (6183
participants). Delay was multifactorial, individual and
complex. Factors contributing to delay included: poor
symptom and risk factor knowledge; fear of detecting
breast abnormality; fear of cancer treatments; fear of
partner abandonment; embarrassment disclosing
symptoms to healthcare professionals; taboo and
stigmatism. Presentation appears quicker following
disclosure. Influence of fatalism and religiosity on
delay is unclear from evidence in these studies. We
compared older studies (e10 years) with newer ones
( studies, delaying factors included: inaccessibility of
healthcare services; competing priorities and
concerns about partner abandonment. Partner
abandonment was studied in older studies but not in
newer ones. Comparisons of healthy women and
cancer populations revealed differences between how
people perceive they would behave, and actually
behave, on finding breast abnormality.
Conclusions: Strategies to improve early
presentation and diagnosis with breast cancer among
black women need to address symptom recognition
and interpretation of risk, as well as fears of the
consequences of cancer. The review is limited by the
paucity of studies conducted outside the USA and
limited detail reported by published studies
preventing comparison between ethnic groups.
Background: As the number of breast cancer survivors continues to rise, Western populations become more ethnically and socially diverse and healthcare resources become ever-more stretched, follow-up that focuses on monitoring for recurrence is no longer viable. New models of survivorship care need to ensure they support selfmanagement and are culturally appropriate across diverse populations. This study explored experiences and expectations of a multi-ethnic sample of women with breast cancer regarding post-treatment care, in order to understand potential barriers to receiving care and inform new models of survivorship care.
Methods: A phenomenological qualitative research design was employed. In-depth interviews were conducted with women from diverse socio-demographic backgrounds in England, who completed treatment for breast cancer in the 12 months prior to the study. Data were analysed using Framework Analysis.
Results: Sixty-six women participated and reported expectations and needs were unmet at follow-up. Whilst there were more commonalities in experiences, discernible differences, particularly by ethnicity and age, were identified relating to three key themes: emotional responses on transition to follow-up; challenges communicating with healthcare professionals at follow-up; and challenges finding and accessing information and support services to address unmet needs.
Conclusions: There are cultural differences in the way healthcare professionals and women communicate, not necessarily differences in their post-treatment needs. We do not know if new models of care meet survivors? needs, or if they are appropriate for everyone. Further testing and potential cultural and linguistic adaptation of models of care is necessary to ensure their appropriateness and acceptability to survivors from different backgrounds. New ways of providing survivorship care mean survivors will need to be better prepared for the post-treatment period and the role they will have to play in managing their symptoms and care.
Cancer-related fatigue (CRF) is a frequent and distressing symptom experienced after cancer treatment. RESTORE is the first web-based resource designed to enhance self-efficacy to manage CRF following curative-intent treatment. The aim of this study is to test the proof of concept and inform the design of an effectiveness trial.
A multi-centre parallel-group two-armed (1:1) exploratory randomised controlled trial (RCT) with qualitative process evaluation was employed in the study. Participants (e18 years; d5 years post treatment with moderate to severe fatigue) were recruited and randomly assigned to RESTORE or a leaflet. Feasibility and acceptability were measured by recruitment, attrition, intervention adherence, completion of outcome measures and process evaluation. Change in self-efficacy to manage CRF was also explored. Outcome measures were completed at baseline (T0), 6 weeks (T1) and 12 weeks (T2). Data were analysed using mixed-effects linear regression and directed content analysis.
One hundred and sixty-three people participated in the trial and 19 in the process evaluation. The intervention was feasible (39 % of eligible patients consented) and acceptable (attrition rate 36 %). There was evidence of higher fatigue self-efficacy at T1 in the intervention group vs comparator (mean difference 0.51 [?0.08 to 1.11]), though the difference in groups decreased by 12 weeks. Time since diagnosis influenced perceived usefulness of the intervention. Modifications were suggested.
Proof of concept was achieved. The RESTORE intervention should be subject to a definitive trial with some adjustments. Provision of an effective supportive resource would empower cancer survivors to manage CRF after treatment completion.
Risk profiling of oncology patients based on their symptom experience assists clinicians to provide more personalized symptom management interventions. Recent findings suggest that oncology patients with distinct symptom profiles can be identified using a variety of analytic methods.
To evaluate the concordance between the number and types of subgroups of patients with distinct symptom profiles using latent class analysis (LCA) and K-modes analysis.
Using data on the occurrence of 25 symptoms from the Memorial Symptom Assessment Scale (MSAS), that 1329 patients completed prior to their next dose of chemotherapy (CTX), Cohen?s kappa coefficient was used to evaluate for concordance between the two analytic methods. For both LCA and K-modes, differences among the subgroups in demographic, clinical, and symptom characteristics, as well as quality of life outcomes were determined using parametric and nonparametric statistics.
Using both analytic methods, four subgroups of patients with distinct symptom profiles were identified (i.e., All Low, Moderate Physical and Lower Psychological, Moderate Physical and Higher Psychological, All High). The percent agreement between the two methods was 75.32% which suggests a moderate level of agreement. In both analyses, patients in the All High group were significantly younger and had a higher comorbidity profile, worse MSAS subscale scores, and poorer QOL outcomes.
Both analytic methods can be used to identify subgroups of oncology patients with distinct symptom profiles. Additional research is needed to determine which analytic methods and which dimension of the symptom experience provides the most sensitive and specific risk profiles.
Patients with Distinct Symptom Experiences, Journal of Pain and Symptom Management 55 (2) pp. 318-333 Elsevier
Risk profiling of oncology patients based on their symptom experience assists
clinicians to provide more personalized symptom management interventions. Recent findings
suggest that oncology patients with distinct symptom profiles can be identified using a variety of
To evaluate the concordance between the number and types of subgroups of
patients with distinct symptom profiles using latent class analysis (LCA) and K-modes analysis.
Using data on the occurrence of 25 symptoms from the Memorial Symptom
Assessment Scale (MSAS), that 1329 patients completed prior to their next dose of
chemotherapy (CTX), Cohen?s kappa coefficient was used to evaluate for concordance between
the two analytic methods. For both LCA and K-modes, differences among the subgroups in
demographic, clinical, and symptom characteristics, as well as quality of life outcomes were
determined using parametric and nonparametric statistics.
Using both analytic methods, four subgroups of patients with distinct symptom profiles
were identified (i.e., All Low, Moderate Physical and Lower Psychological, Moderate Physical
and Higher Psychological, All High). The percent agreement between the two methods was
75.32% which suggests a moderate level of agreement. In both analyses, patients in the All
High group were significantly younger and had a higher comorbidity profile, worse MSAS
subscale scores, and poorer QOL outcomes.
Both analytic methods can be used to identify subgroups of oncology patients with
distinct symptom profiles. Additional research is needed to determine which analytic methods
and which dimension of the symptom experience provides the most sensitive and specific risk
Lymphedema is a common consequence of breast cancer treatment requiring life-long treatment to reduce
symptoms and prevent complications. Evidence to inform the optimal decongestive lymphedema treatment
package is lacking.
To identify the effect of decongestive lymphedema treatment on excess arm volume or patient-centered
outcomes for women presenting within either 12 months or mean 9 months of developing arm lymphedema
following breast cancer treatment.
Types of participants: women who received lymphedema treatment within either 12 months or mean 9
months of developing unilateral breast cancer-related arm lymphedema.
Types of intervention: any decongestive lymphedema treatment delivered with the purpose of reducing arm
lymphedema, compared to another form of lymphedema treatment (whether self or practitioner
administered), placebo or no treatment.
Types of outcomes: clinical outcome was excess arm volume; patient-centered outcomes were health
related quality of life, arm heaviness, arm function, patient-perceived benefit and satisfaction with treatment.
Types of studies: experimental study designs were eligible, including randomized and non-randomized
controlled trials, quasi-experimental, prospective and retrospective before and after studies.
A three-step search strategy was utilized to find published and unpublished studies. The search identified
studies published from inception of each database to 6th July 2016. Reference lists were scanned to identify
further eligible studies.
Studies were critically appraised using appropriate standardized critical appraisal instruments from The
Joanna Briggs Institute.
Details describing each study and treatment results regarding outcomes of interest were extracted from
papers included in the review using appropriate standardized data extraction tools from The Joanna Briggs
Due to heterogeneity in included studies, results for similar outcome measures were not pooled in statistical
meta-analysis. A narrative and tabular format was used to synthesize results from identified and included
Seven studies reporting results for outcomes of interest were critically appraised and included in the review:
five randomized controlled trials and two descriptive (uncontrolled) studies. Reported outcomes included
excess arm volume (five studies), health-related quality of life (three studies), arm heaviness (one study),
arm function (two studies) and patient-perceived benefit (two studies). There was some evidence that
decongestive treatments were effective for women presenting within either 12 months or mean 9 months
of developing breast cancer-related arm lymphedema, but the wide range of data prevented comparison of
treatment findings which limited our ability to answer the review questions.
Weak evidence (grade B) for the impact of decongestive lymphedema treatment on women with early
lymphedema (i.e. less than 12 months duration of BCRL symptoms) did not allow any conclusions to be
drawn about the most effective treatment to be offered when these women first present for treatment.
Findings provided no justification to support change to current practice.
Future primary research needs to focus on the most effective treatment for women when they first present
with lymphedema symptoms, e.g. treatment provided within 12 months of developing symptoms. Studies
should be adequately powered and recruit women exclusively with less than 12 months duration of BCRL
symptoms, provide longer follow-up to monitor treatment effect over time, with comparable treatment
protocols, outcome measures and reporting methods.
Objectives: Walking is an adaptable, inexpensive and accessible form of physical activity. However its impact on quality of life and symptom severity in people with advanced cancer is unknown. This study aimed to assess the feasibility and acceptability of a randomised controlled trial (RCT) of a community-based walking intervention to enhance quality of life (QoL) in people with recurrent/metastatic cancer.
Design: We used a mixed-methods design comprising a two-centre RCT and nested qualitative interviews. Participants: Patients with advanced breast, prostate, gynaecological or haematological cancers randomised 1:1 between intervention and usual care.
Intervention: The intervention comprised Macmillan?s ?Move More? information, a short motivational interview with a recommendation to walk for at least 30 minutes on alternate days and attend a volunteer-led group walk weekly.
Outcomes: we assessed feasibility and acceptability of the intervention and RCT by evaluating study processes (rates of recruitment, consent, retention, adherence and adverse events), and using end of study questionnaires and qualitative interviews. Patient reported outcome measures (PROMS) assessing quality of life (QoL), activity, fatigue, mood and self-efficacy were completed at baseline and 6, 12 and 24 weeks.
Results: We recruited 42 (38%) of eligible participants. Recruitment was lower than anticipated (goal n=60), the most commonly reported reason being unable to commit to walking groups (n=19). Randomisation procedures worked well with groups evenly matched for age, sex and activity. By week 24, there was a 45% attrition rate. Most PROMs whilst acceptable were not sensitive to change and did not capture key benefits.
Conclusions: The intervention was acceptable, well tolerated and the study design was judged acceptable and feasible. Results are encouraging and demonstrate that exercise was popular and conveyed benefit to participants. Consequently, an effectiveness RCT is warranted, with some modifications to the intervention to include greater tailoring and more appropriate PROMs selected.
The purpose of the eSMART (Electronic Symptom Management using the Advanced Symptom Management System (ASyMS) Remote Technology) study is to evaluate the use of mobile phone technology to manage chemotherapy-related toxicities (CRTs) in people with breast cancer (BC), colorectal cancer (CRC), Hodgkin's lymphoma (HL), and non-Hodgkin lymphoma (NHL)) across multiple European sites. One key objective was to review the published and grey literature on assessment and management of CRTs among patients receiving primary chemotherapy for BC, CRC, HL, and NHL to ensure that ASyMS remained evidence-based and reflected current and local practice.
Three electronic databases were searched for English papers, with abstracts available from 01/01/2004-05/04/2014. For the grey literature, relevant clinical practice guidelines (CPGs)/evidence-based resources (EBRs) from the main international cancer organisations were reviewed as were symptom management (SM) protocols from the sites.
After full-text screening, 27 publications were included. The majority (n = 14) addressed fatigue and focused on BC patients. Relevant CPGs/EBRs were found for fatigue (n = 4), nausea/vomiting (n = 5), mucositis (n = 4), peripheral neuropathy (n = 3), diarrhoea (n = 2), constipation (n = 2), febrile neutropenia/infection (n = 7), palmar plantar erythrodysesthesia (PPE) (n = 1), and pain (n = 4). SM protocols were provided by >40% of the clinical sites.
A need exists for empirical research on SM for PPE, diarrhoea, and constipation. Research is needed on the efficacy of self-care strategies in patients with BC, CRC, HL, and NHL. In general, consistency exists across CPGs/EBRs and local guidelines on the assessment and management of common CRTs.
Purpose: To identify potential candidate predictors of anxiety in women with early stage breast cancer (BC) after adjuvant treatments and evaluate methodological development of existing multivariable models to inform the future development of a predictive risk stratification model (PRSM).
Methods: Databases (MEDLINE, Web of Science, CINAHL, CENTRAL and PsycINFO) were searched from inception to November 2015. Eligible studies were prospective, recruited women with stage 0-3 BC, used a validated anxiety outcome e 3 months' post-treatment completion and used multivariable prediction models. Internationally accepted quality standards were used to assess predictive risk of bias and strength of evidence.
Results: Seven studies were identified, five were observational cohorts and two secondary analyses of RCTs. Variability of measurement and selective reporting precluded meta-analysis. Twenty-one candidate predictors were identified in total. Younger age and previous mental health problems were identified as risk factors in e 3 studies. Clinical variables (e.g. treatment, tumour grade) were not identified as predictors in any studies. No studies adhered to all quality standards.
Conclusions: Pre-existing vulnerability to mental health problems and younger age increased the risk of anxiety after completion of treatment for BC survivors, but there was no evidence that chemotherapy was a predictor. Multiple predictors were identified but many lacked reproducibility or were not measured across studies, and inadequate reporting did not allow full evaluation of the multivariable models. The use of quality standards in the development of PRSM within supportive cancer care would improve model quality and performance thereby allowing professionals to better target support for patients.
increasing. Cancer survivors face a range of problems following primary treatment. One of the most frequently
reported and distressing symptoms experienced by cancer survivors is fatigue. There is growing support for
survivors who are experiencing problems after cancer treatment to engage in supported self-management. To date
there is some evidence of effective interventions to manage fatigue in this population; however, to our knowledge
there are no online resources that draw on this information to support self-management of fatigue. This paper
describes the protocol for an exploratory randomized controlled trial of an online intervention to support
self-management of cancer-related fatigue after primary cancer treatment.
Methods/design: This is a parallel-group two-armed (1:1) exploratory randomized controlled trial including 125
cancer survivors experiencing fatigue (scoring e4 on a unidimensional 11-point numeric rating scale for fatigue
intensity) within five years of primary treatment completion with curative intent. Participants will be recruited from
13 NHS Trusts across the UK and randomized to either the online intervention (RESTORE), or a leaflet comparator
(Macmillan Cancer Backup, Coping with Fatigue). The primary outcome is a change in Perceived Self-Efficacy for
Fatigue Self-Management (as measured by the Perceived Self-Efficacy for Fatigue Self-Management Instrument).
Secondary outcomes include impact on perception and experience of fatigue (measured by the Brief Fatigue
Inventory), and quality of life (measured by the Functional Assessment of Cancer Therapy - General and the
Personal Wellbeing Index). Outcome measures will be collected at baseline, 6 weeks (completion of intervention),
and 3 months. Process evaluation (including telephone interviews with recruiting staff and participants) will
determine acceptability of the intervention and trial processes.
Discussion: Data from this trial will be used to refine the intervention and contribute to the design of an
effectiveness trial. This intervention will be expanded to address other cancer-related problems important to cancer
survivors following primary cancer treatment.
Prostate cancer (PC) is common and affects Black African and Caribbean men disproportionately more than White men. It is known that PC awareness is low in these groups, but knowledge is lacking about other factors that may deter Black men from seeking information about, or getting tested for, PC. The aim of this review was to appraise research on knowledge and perceptions of PC among Black men.
Four medical and social science databases were systematically searched, and reference lists of relevant papers were hand searched. Non-English publications were excluded. Qualitative findings were synthesised using comparative thematic analysis to which quantitative findings were integrated.
Thirteen qualitative studies and 20 cross-sectional surveys were included. All except two were conducted in the USA. The analysis identified individual, cultural and social factors likely to impact on Black men's awareness of, and willingness to be tested for, PC. Black men's awareness of personal risk of PC varied greatly between studies. Misunderstandings regarding methods of diagnosis and treatment were widespread. PC testing and treatment were perceived as a threat to men's sense of masculinity. Mistrust of the health-care system, limited access to health care and lack of trusting relationships with health professionals were also prominent.
The factors impacting on Black men's awareness of PC may contribute to late PC diagnosis and should be taken into account when communicating with Black men seeking prostate care. Further, the review demonstrated a need for high-quality studies in countries other than the USA to determine the relevance of the review findings for Black men in other nations and continents.
To estimate prevalence and severity of patients' self-perceived supportive care needs in the immediate post-treatment phase and identify predictors of unmet need.
Patients and Methods
A multicenter, prospective, longitudinal survey was conducted. Sixty-six centers recruited patients for 12 weeks. Patients receiving treatment for the following cancers were recruited: breast, prostate, colorectal, and gynecologic cancer and non-Hodgkin's lymphoma. Measures of supportive care needs, anxiety and depression, fear of recurrence, and positive and negative affect were completed at the end of treatment (T0) and 6 months later (T1).
Of 1,850 patients given questionnaire packs, 1,425 (79%) returned questionnaires at T0, and 1,152 (62%) returned questionnaires at T1. Mean age was 61 years; and most respondents were female (69%) and had breast cancer (57%). Most patients had no or few moderate or severe unmet supportive care needs. However, 30% reported more than five unmet needs at baseline, and for 60% of these patients, the situation did not improve. At both assessments, the most frequently endorsed unmet needs were psychological needs and fear of recurrence. Logistic regression revealed several statistically significant predictors of unmet need, including receipt of hormone treatment, negative affect, and experiencing an unrelated significant event between assessments.
Most patients do not express unmet needs for supportive care after treatment. Thirty percent reported more than five moderate or severe unmet needs at both assessments. Unmet needs were predicted by hormone treatment, negative mood, and experiencing a significant event. Our results suggest that there is a proportion of survivors with unmet needs who might benefit from the targeted application of psychosocial resources.
of whom experience reduced quality of life resulting from the physical and psychosocial
consequences of cancer and its treatment. While drug treatments are important at alleviating
some symptoms, there is increasing evidence of the benefits of exercise in enhancing
quality of life and health outcomes. Walking is an inexpensive and accessible form of
exercise. To our knowledge, no studies have investigated whether a walking intervention is
sufficient to enhance quality of life and alleviate symptoms in people with recurrent or
metastatic cancer across a range of tumor types. This paper describes the CanWalk study
protocol, which aims to assess the feasibility and acceptability of undertaking a randomized
controlled trial of a community-based walking program to enhance quality of life and well &
Children need to be prepared for the death of a parent and supported afterwards. Parents seek support from health and social care professionals to prepare their children. Support is not always forthcoming.
To systematically identify, analyse and synthesise literature reporting of the experiences of health and social care professionals when supporting parents and children during, and following, the death of a parent.
A systematically constructed qualitative review and thematic synthesis. Registered on Prospero (CRD42017076345).
MEDLINE, CINAHL, Embase, PsycINFO, PsycARTICLES and PROSPERO, searched from January 1996 to July 2018 for qualitative studies in English, containing verbatim reporting of health and social care professionals? experiences of supporting parents and children during, and following, the death of a parent. Qualitative data were appraised using a modified Critical Appraisal Skills Programme qualitative appraisal checklist.
The search yielded 15,758 articles. Of which, 15 met the inclusion criteria. A total of 13 included professionals? experiences of supporting parents and children before parental death. Two included experiences of supporting surviving parents and children afterwards. Three analytical themes identified as follows: (1) aspiring to deliver family-focussed care, (2) health and social care professionals? behaviours and emotions and (3) improving connections with parents and children. Connecting empathically with parents and children to prepare and support children entails significant emotional labour. Professionals seek to enhance their confidence to connect.
Professionals struggle to connect empathically with parents and their children to prepare and to support children when a parent is dying and afterwards. Awareness of professionals? needs would enable provision of appropriate support for parents and children.
Computational tools that predict the course and severity of these symptoms have the
potential to assist oncology clinicians to personalize the patient's treatment regimen
more efficiently and provide more aggressive and timely interventions. Three common
and inter-related symptoms in cancer patients are depression, anxiety, and sleep
disturbance. In this paper, we elaborate on the efficiency of Support Vector Regression
(SVR) and Non-linear Canonical Correlation Analysis by Neural Networks (n-CCA) to
predict the severity of the aforementioned symptoms between two different time points
during a cycle of chemotherapy (CTX). Our results demonstrate that these two
methods produced equivalent results for all three symptoms. These types of predictive
models can be used to identify high risk patients, educate patients about their symptom
experience, and improve the timing of pre-emptive and personalized symptom
following treatment for head and neck cancer in a UK population?.,
The premise of this study was that hearing deterioration, associated with treatment for head and neck cancer, has a negative impact on patients? quality of life. However, there have been no studies to assess this phenomenon in people receiving current UK treatment, and there is little information on the impact of subsequent hearing deterioration.
This study, conducted in one UK hospital, aimed to investigate the incidence and severity of hearing deterioration, and patient experience of it, following treatment for head and neck cancer.
A sequential mixed methods explanatory design was chosen as it was the most appropriate for addressing the research aims. A critical realist framework underpinned the study. A prospective observational repeated measures design was employed to obtain quantitative data in Phase 1 of the study to assess changes in hearing at the end of treatment, and at 3-month follow-up post-treatment, using pre-treatment test level comparison. The Common Terminology Criteria for Adverse Events (version 4.03) were used to determine the incidence and severity of hearing deterioration. Results from Phase 1 were used to inform selection of participants for Phase 2 of the study. An approach informed by phenomenology using interview methodology, was used to explore patient experience of hearing deterioration.
Fifty adults who had been diagnosed with head and neck cancer were recruited to Phase 1 of the study using a consecutive sampling approach. These participants were due to receive standard UK curative radiotherapy (intensity modulated radiotherapy) or chemoradiotherapy (including the use of cisplatin or carboplatin). From the 50 participants recruited, 13 who had hearing deterioration were selected using purposive sampling for one-to-one interviews to obtain in-depth information on their experience of hearing loss.
The incidence of hearing deterioration was 57% in the 42 participants who completed testing at the end of treatment, and 50% percent in those who completed 3-month follow-up testing. At 3-month follow-up, 26% of participants had major (Grade 3) hearing deterioration in at least one ear. Patients who had chemoradiotherapy were more likely to experience hearing deterioration compared with those who had had radiotherapy only (p=0.01). Older patients were more at risk of hearing deterioration than younger participants (p=0.03), but if hearing deterioration occurred it appeared that younger patients suffered more severe deterioration than older patients (p=0.02).
Aural change (including hyperacusis) experienced by some participants during treatment required a change in treatment regimen for them. Participants reporting either minor (Grade 1) or major hearing deterioration were adversely affected by their aural symptoms that manifested with treatment, and the impact of tinnitus (the incidence of which is not covered by existing studies), was extensive in head and neck cancer survivors. Another emerging finding in this study was that middle ear dysfunction, in the early post treatment phase, had a negative impact on patient experience. A further novel finding was that participants with bilateral mild-moderate or moderate severity, mid-high frequency sudden-onset hearing loss required lip-reading to assist their communication.
There was evidence that some participants played down their aural symptoms, yet hearing deterioration had a negative impact on their overall quality of life, including generating a sense of loss (principally in older patients) and isolation (associated with younger patients). Finally, there was varied experience among participants receiving information on their hearing test results and on the process of receiving support for their hearing and tinnitus concerns.
Conclusions and recommendations
This current study provides evidence that could be used to increase awareness of the potential scale and impact of hea
People engage in health information-seeking online when experiencing unusual or unfamiliar bodily changes. It is not well understood how people consult the Internet for health information after the onset of unfamiliar symptoms and before receiving a potential diagnosis, and how online information-seeking can help people appraise their symptoms. This lack of evidence may be partly due to methodological limitations in capturing in real time the online information-seeking process.
We explored women?s symptom attribution and online health information-seeking in response to a hypothetical and unfamiliar breast change suggestive of cancer (nipple rash). We also aimed to establish the feasibility of capturing in real time the online information-seeking process with a tool designed to track participants? online searches and visited websites, the VIZZATATM browser tracker.
An online survey was completed by 56 cancer-free women (Mage = 60.34 years, SD = 7.73 years) responding to a scenario asking them to imagine noticing a red scaly rash on the nipple. Participants were asked to make symptom attributions when presented with the scenario (Time1) and again after seeking information online (Time2). The online tracking tool, embedded in the survey, was used to capture in real time participants? search terms and accessed websites.
The tracking tool captured the search terms and accessed websites of most of the participants (46/56, 82%). For the rest (n=10, 18%), there was evidence of engagement in online information-seeking, e.g. medical terminology and cancer attribution at Time2, despite their searching activity not being recorded. Twenty five participants considered cancer as a potential cause for the nipple rash at Time1, yet only one of these used ?cancer? as a search term. Most participants (n=40, 87%) used rash-related search terms, particularly ?nipple rash? and ?rash on nipple?. The majority (41/46, 89%) accessed websites containing breast cancer information, with the NHS webpage ?Paget?s disease of the nipple? being the most visited one. At Time2, after engaging in the Internet search task, more participants attributed the nipple rash to breast cancer than at Time1, n=37 (66.1%) vs. n=25 (44.6%), although a small number of participants (n=6) changed from making a cancer attribution at Time1 to a non-cancer one at Time2.
Making a cancer attribution for an unfamiliar breast change did not necessarily translate into cancer-termed searches. Equally, not all Internet searches led to a cancer attribution. The findings suggest that online information-seeking may not necessarily help women who experience unfamiliar breast cancer symptoms understand their condition. Despite some technical issues, this study showed that it is feasible to use an online browser tracking tool to capture in real time information-seeking about unfamiliar symptoms.
Background: There has been an international shift in health care, which has seen an increasing focus and development of technological and personalized at-home interventions that aim to improve health outcomes and patient-clinician communication. However, there is a notable lack of empirical evidence describing the preparatory steps of adapting and implementing technology of this kind across multiple countries and clinical settings.
Objective: This study aimed to describe the steps undertaken in the preparation of a multinational, multicenter randomized controlled trial (RCT) to test a mobile phone?based remote symptom monitoring system, that is, Advanced Symptom Management System (ASyMS), designed to enhance management of chemotherapy toxicities among people with cancer receiving adjuvant chemotherapy versus standard cancer center care.
Methods: There were 13 cancer centers across 5 European countries (Austria, Greece, Ireland, Norway, and the United Kingdom). Multiple steps were undertaken, including a scoping review of empirical literature and clinical guidelines, translation and linguistic validation of study materials, development of standardized international care procedures, and the integration and evaluation of the technology within each cancer center.
Results: The ASyMS was successfully implemented and deployed in clinical practices across 5 European countries. The rigorous and simultaneous steps undertaken by the research team highlighted the strengths of the system in clinical practice, as well as the clinical and technical changes required to meet the diverse needs of its intended users within each country, before the commencement of the RCT.
Conclusions: Adapting and implementing this multinational, multicenter system required close attention to diverse considerations and unique challenges primarily related to communication and clinical and technical issues. Success was dependent on collaborative and transparent communication among academics, the technology industry, translation partners, patients, and clinicians as well as a simultaneous and rigorous methodological approach within the 5 relevant countries.